Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab

@inproceedings{Yilmaz2013EarlyII,
  title={Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab},
  author={Sedat Yilmaz and Ismail Simşek},
  booktitle={Therapeutics and clinical risk management},
  year={2013}
}
Tocilizumab is a fully humanized monoclonal antibody against interleukin-6 receptors that was approved for the treatment of patients with rheumatoid arthritis (RA). Several lines of evidence, obtained both from conventional disease-modifying anti-rheumatic drugs (DMARDs) and tumor necrosis factor (TNF) inhibitors, have supported the concept of "window of… CONTINUE READING